Abstract
Increased free light chain (FLC) levels have been reported as useful in various autoimmune conditions. We investigated how FLC concentrations change upon B cell targeted therapy in systemic lupus erythematosus (SLE) patients and if they correlate with disease activity. We retrospectively studied 11 SLE patients without renal failure, whom were treated with rituximab. Quantitative determination of IgG, IgA, IgM, and serum FLC was performed before and after rituximab. At baseline, 70% had abnormal serum FLC levels, including increased kappa and lambda levels, while the kappa/lambda ratio was normal for all. A strong correlation was observed between complement C3 fraction and kappa levels (r = −0.929, P < 0.001) or lambda levels (r = −0.854, P = 0.003), but not with IgG, IgA, or IgM levels. After rituximab treatment, kappa and lambda FLC concentrations decreased significantly whilst total concentrations of IgG, IgA, and IgM also decreased but remained within the normal range. There was a strong correlation only between kappa FLC levels and complement C3 fraction consumption (r = −0.543, P = 0.003). In SLE patients without renal failure, increased FLC levels (mainly kappa) with normal kappa/lambda ratios are a common feature, and in contrast to total IgG levels, FLC concentrations correlate with biological disease activity.
References
Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47:673–680
Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M et al (2007) Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 66:23–27
Terrier B, Sene D, Saadoun D, Ghillani-Dalbin P, Thibault V, Delluc A et al (2009) Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis 68:89–93
Hoffman U, Opperman M, Kuchler S, Ventur Y, Teuber W, Michels H et al (2003) Free immunoglobulin light chains in patients with rheumatic diseases. Z Rheumatol 62:Fr40a
Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthitis Rheum 46:2673–2677
Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthitis Rheum 50:2580–2589
Smith KGC, Jones RB, Burns SM, Jayne DRW (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. Arthitis Rheum 54:2970–2982
Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48:1437
Urban S, Oppermann M, Reucher SW, Schmolke M, Hoffmann U, Hiefinger-Schindlbeck R, Helmke KH (2004) Free light chains (FLC) of immunoglobulins as parameter resembling disease activity in autoimmune rheumatic diseases. Ann Rheum Dis 63:141a
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222–233
Tew GW, Rabbee N, Wolslegel K, Hsieh HJ, Monroe JG, Behrens TW, Brunetta PG, Keir ME (2010) Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus 19:146–157
Kormelink TG, Tekstra J, Thurlings RM, Boumans MH, Vos K, Tak PP, Bijlsma JW, Lafeber FP, Redegeld FA, van Roon JA (2010) Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann Rheum Dis 69:2137–2144
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chiche, L., Cournac, J., Mancini, J. et al. Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. Clin Rheumatol 30, 685–689 (2011). https://doi.org/10.1007/s10067-010-1674-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-010-1674-1